Welcome to our dedicated page for Lunai Bioworks news (Ticker: LNAI), a resource for investors and traders seeking the latest updates and insights on Lunai Bioworks stock.
Lunai Bioworks Inc. develops AI-enabled life sciences platforms for drug discovery, precision therapeutics and chemical defense applications. Company news centers on the Augusta platform, BioSymetrics' phenotypic screening and machine-learning capabilities, and programs tied to central nervous system diseases, oncology and biodefense.
Recurring updates include intellectual property additions, patent issuances, commercial collaborations, defense-focused chemical threat assessment work, and capital transactions used to support platform expansion. Recent company developments also cover CNS delivery technologies, neurotherapeutic patent assets, patient-stratification methods, and the integration of clinical, genomic and phenotypic data into drug discovery workflows.
Lunai Bioworks (NASDAQ:LNAI) subsidiary BioSymetrics and academic partners published a Nature Communications study (Oct 16, 2025) reporting prognostic serum protein biomarkers for Duchenne muscular dystrophy (DMD).
The multi‑institutional analysis used the SomaScan proteomics platform on >700 longitudinal serum samples from European and U.S. cohorts and identified proteins including RGMA, ART3, and ANTXR2 that associate with motor performance and predict outcomes such as loss of ambulation and upper‑limb decline.
Authors say these minimally invasive biomarkers could refine clinical trial enrollment, improve stratification, and support more personalized patient management, while results were cross‑cohort validated and controlled for age and corticosteroid use.
Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq staff had notified the company on April 14, 2025 that LNAI's common stock failed to maintain a $1.00 minimum bid over the prior 30 business days. Staff determined the closing bid price was at or above $1.00 for 11 consecutive business days from September 30, 2025 through October 14, 2025, restoring compliance and leaving the company eligible to remain listed on The Nasdaq Capital Market. Management said the milestone supports its focus on advancing an AI-powered platform for drug discovery and biodefense.
Lunai Bioworks (Nasdaq:LNAI) launched a preclinical Alzheimer's program using its AI platform Augusta, reporting up to a 35% improvement in diagnostic accuracy by combining MRI, genomics, and metabolomics versus MRI alone. BioSymetrics, a wholly owned subsidiary, signed its first commercial contract last week to identify early Alzheimer's markers. Results were benchmarked on the ADNI dataset and used automated optimization across 22,000 MRI processing runs. The platform supports real-time distributed analysis via cloud architecture and is positioned to extend prior Parkinson's findings into broader neurodegenerative diagnostics.
Lunai Bioworks (NASDAQ:LNAI), formerly known as Renovaro Inc., has unveiled its new corporate identity alongside a 10:1 reverse stock split that reduces outstanding shares from 231.8 million to 23.2 million. The company's rebranding reflects its strategic focus on AI-powered drug discovery and biodefense.
Key developments include the launch of a proprietary transformer-based platform for neurotoxicity intelligence, advancement of a preclinical Parkinson's Disease biomarker program through subsidiary BioSymetrics, and securing a multi-year NIH STTR grant. The company's Augusta platform aims to advance precision neurology through AI-integrated therapeutics and biomarker intelligence.